Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer (Cornerstone001)
A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)
The purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2-low expression (IHC 1+ or 2+ and ISH-) and hormone receptor-negative(ER-, PR-) breast cancer with residual disease after neoadjuvant treatment.
Patients will be randomized 1:1 to either the Experimental arm (combination of AST-301/rhuGM CSF and standard adjuvant therapy) or the Control arm (combination of placebo/rhuGM CSF and standard adjuvant therapy). Standard adjuvant chemotherapy will be pembrolizumab or capecitabine.
Adjuvant therapy will be administered in compliance with the NCCN guideline for breast cancer (Version 8, 2021), and IP (AST-301) will be administered 3 times every 3 weeks in the adjuvant treatment period, with a booster administered at 24 weeks (±7 days) post the third dose of IP administration.
Survival follow up will be performed to determine invasive Disease Free survival(iDFS).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Eunkyo Joung, CMO
- Phone Number: 02-2038-2347
- Email: eunkyo.joung@astonsci.com
Study Contact Backup
- Name: Aston Sci. Inc,
- Email: astonsci@astonsci.com
Study Locations
-
-
-
Changhua City, Taiwan, 500
- Changhua Christian Hospital
-
Kaohsiung, Taiwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Taichung City, Taiwan, 404
- China Medical University Hospital
-
Tainan, Taiwan, 710
- Chi Mei Medical Center
-
Taipei City, Taiwan, 112
- Taipei Veterans General Hospital
-
Taipei City, Taiwan, 112
- National Taiwan University Hospital
-
Taipei city, Taiwan, 11259
- Koo Foundation Sun Yat-Sen Cancer Center
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Ironwood Cancer and Research Centers
-
-
California
-
La Jolla, California, United States, 92037
- Scripps Health
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68130
- Nebraska Cancer Specialist
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center Research
-
Columbus, Ohio, United States, 43623
- The Ohio State University Comprehensive Cancer Center
-
Toledo, Ohio, United States, 43623
- Toledo Clinic Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Institute
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Has a residual invasive cancer in the breast(non-pCR) after neoadjuvant treatment
- Has stage I, II, or III disease prior to surgery per American Joint Committee on Cancer (AJCC)
- HER 2 1+ by IHC or HER2 2+by IHC without gene amplification by ISH, as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
- Hormone receptor (ER and PR) negative by ASCO/CAP guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Demonstrates adequate organ function.
Key Exclusion Criteria:
- Has a history of hypersensitivity or other contraindications to rhGM-CSF
- Has a history of invasive malignancy ≤5 years prior to first administration of investigational drug except for adequately treated non-melanoma skin cancer or carcinoma in situ.
- Is on immune suppression therapy or has a history of immune suppression therapy ≤4 weeks prior to the first administration of investigational drugs
- Has a history of autoimmune disease or inflammatory disease
- Has active infection including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
- Is pregnant or breastfeeding or expecting to conceive children
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AST-301(pNGVL3-hICD)+Chemotherapy
|
Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
Other Names:
Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
Other Names:
Q3W; IV infusion
Other Names:
On days 1-14 (Q3W), BID ; Oral administration,
Other Names:
|
|
Active Comparator: Placebo + Chemotherapy
|
Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
Other Names:
Q3W; IV infusion
Other Names:
On days 1-14 (Q3W), BID ; Oral administration,
Other Names:
Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
2-year invasive disease free survival rate (iDFS)
Time Frame: Overall study period approximately up to 4years (End of study in this study is defined as 2years frm the date of last Patient In.
|
iDFS event is defined as Ipsilateral breast tumor recurrence Local/regional invasive recurrence Distant recurrence Invasive contralateral breast cancer Death (from breast cancer/non-breast cancer cause/unknown cause) Secondary primary invasive cancer (non-breast)
|
Overall study period approximately up to 4years (End of study in this study is defined as 2years frm the date of last Patient In.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AST-301 specific T cell immune responses
Time Frame: Up to approximately 82 weeks
|
Immune response will be assessed by IFN-gamma enzyme-linked immune absorbent spot (ELISpot) assay
|
Up to approximately 82 weeks
|
|
Change in central memory T cell populations
Time Frame: Up to approximately 82 weeks
|
Assessment by FACS
|
Up to approximately 82 weeks
|
|
Distant Recurrence-Free Survival rate, dRFS rate
Time Frame: Overall study period approximately up to 4 years
|
dRFS rate at the end of study
|
Overall study period approximately up to 4 years
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE
Time Frame: Overall study period approximately up to 4years
|
To assess safety of AST-301 administered in breast cancer patients.
|
Overall study period approximately up to 4years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Capecitabine
- Pembrolizumab
- Sargramostim
Other Study ID Numbers
Other Study ID Numbers
- PN-301-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.